new Year Drug Price Rises In italy

15 January 1996

In Italy, 4,600 drugs classified as A and B (free or 50% free to patients under the health service) received new Year price rises, as the price decreases imposed by the 1995 budget bill elapsed.

The pharmacists' association, federfarma, says prices of about 1,200 products will rise 5%, while for the remaining 3,400 the increase will be 2.5%. The drug manufacturers' association, Farmindustria, says the price adjustment is not really a rise, but simply a return to the situation before the mandatory price cuts of December 1994, and that even reverting to the situation at end-1994 means an actual price decline of 17% for drugs against a rise in inflation of 18% over the last four years. Drug prices in italy remain around 30% below the European average, says Farmindustria.

Meantime, the 1995 ceiling for state spending on drugs has been revised up to 9,700 billion lire ($6.15 billion), from an initial forecast of 9,000 billion lire.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight